AVAnT1A

Antiviral Action against Type 1 Diabetes Autoimmunity

The AVAnT1A study is a randomized, double-blind, placebo-controlled primary prevention trial designed to test the hypothesis that vaccination against COVID-19 in the first year of life can prevent the onset of islet autoimmunity and type 1 diabetes in genetically predisposed children. The trial builds upon findings from POInT, which suggest that COVID-19 is associated with up to a 10-fold increased risk of islet autoimmunity when infection occurs at around one year of age in children with an increased genetic risk for type 1 diabetes.

SARS-CoV-2 Vaccination to prevent Type 1 Diabetes?

The intervention involves administration of full vaccination with approved mRNA vaccine or a placebo starting from the age of 6 months. Spanning five countries (Germany, UK, Poland, Belgium, and Sweden), the study aims to enroll 2252 infants commencing in April 2024 with an expected completion in 2030.

Surveillance of Viral Infections during first years of life.

The study incorporates an intense, unprecedented surveillance of viral infections, accompanied by an extraordinary collection of data and samples. This comprehensive approach seeks to enhance our understanding how viral infections in early life influence immune development, beta-cell function, and risk of islet autoimmunity.